CLAIMS

1. A combination comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and alpelisib.

2. The combination according to claim 1, showing therapeutic synergy.

3. The combination according to claim 1 or claim 2, for use in the treatment of cancer.

4. The combination for use according to claim ~~4~~3, wherein the cancer is breast cancer.

5. The combination and combination for use according to any of claims 1 to 4, wherein 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and alpelisib are administered simultaneously or spaced out over a period of time.

6. A pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and alpelisib, and at least one pharmaceutically acceptable excipient.

7. The pharmaceutical composition according to claim 6, for use in the treatment of cancer.

8. The pharmaceutical composition for use according to claim 7, wherein the cancer is breast cancer.

9. Compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with alpelisib.

10. The compound for use in the treatment of cancer according to claim 9, which is administered separately, simultaneously or spaced out over time, with alpelisib.

11. Alpelisib for use in the treatment of cancer by co-administration with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

12. Alpelisib for use in the treatment of cancer according to claim 11, which is administered separately, simultaneously or spaced out over time, with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical kit comprising:

(i) a first pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;

(ii) a second pharmaceutical composition comprising alpelisib, and at least one pharmaceutically acceptable excipient,

wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments and are intended to be independently administered, each administration with regards to the other one being simultaneous or spaced out over time.